SphingoTec

📍 Hennigsdorf, Germany🗓 Founded 2002👥 45 employees💰 Last funded Oct 2018
Biotechnology Research🌐 sphingotec.com
Website LinkedIn
SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. SphingoTec GmbH was established in 2002 by Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2002
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in SphingoTec?
SphingoTec has 1 investors on record on gritt.io.
When did SphingoTec last raise funding?
The most recent investment in SphingoTec recorded on gritt.io was in October 2018.
When was SphingoTec founded?
SphingoTec was founded in 2002.
What industry is SphingoTec in?
SphingoTec operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SphingoTec based?
SphingoTec is headquartered in Hennigsdorf, Germany.